Substituted heteroaryl compounds and methods of use

1. A compound having Formula (I):

or a stereoisomer, a tautomer, an N-oxide, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, wherein:

Z is C 7 -C 12 spiro bicycloalkyl, C 7 -C 12 fused bicycloalkyl, 7-12 membered spiro heterobicyclyl or 7-12 membered fused heterobicycloalkyl, wherein Z is substituted by 1, 2, 3, 4 or 5 R 2 groups;

Z 1 is H, C 1 -C 12 alkyl, C 3 -C 12 cycloalkyl or 3-12 membered heterocyclyl, wherein each of the C 1 -C 12 alkyl, C 3 -C 12 cycloalkyl and 3-12 membered heterocyclyl is optionally independently substituted by 1, 2, 3, 4 or 5 R 2a groups;

A is

R 1 is H, F, Cl, Br, I, N 3 , CN, —NO 2 , C 1 -C 12 alkyl, C 1 -C 12 alkoxyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 3 -C 12 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, 5-12 membered heteroaryl, —NR 9a R 9b , —OR 9c , —C(═O)OR 9c , —C(═O)NR 9a R 9b or —S(═O) 2 NR 9a R 9b , wherein each of the C 1 -C 12 alkyl, C 1 -C 12 alkoxyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 3 -C 12 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl is optionally independently substituted by 1, 2, 3, 4 or 5 R 11 groups;

each R 2 is independently F, Cl, Br, I, —NO 2 , N 3 , CN, —OH, —NH 2 , —C(═O)CH 2 CN, —NHC(═O)CH 2 CN, —N(CH 3 )C(═O)CH 2 CN, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxyl, C 3 -C 12 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, 5-12 membered heteroaryl, —NR 10a R 10b , —O—(C 0 -C 4 alkylene)-R 10c , —O—(C 1 -C 4 alkylene)-OR 10c , —C(═O)R 10d , —OC(═O)R 10d , —N(R 10e )C(═O)R 10d , —C(═O)NR 10a R 10b , —N(R 10e )C(═O)NR 10a R 10b , —C(═O)N(R 10e )C(═O)R 10d , —S(═O) 2 R 10f , —N(R 10e )S(═O) 2 R 10f or —S(═O) 2 NR 10a R 10b , or two adjacent R 2 taken together with the atoms to which they are attached form a C 3 -C 12 cycloalkyl or 3-12 membered heterocycloalkyl group, wherein each of the C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxyl, C 3 -C 12 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, 5-12 membered heteroaryl, and 3-12 membered heterocycloalkyl group is optionally independently substituted by 1, 2, 3, 4 or 5 R 11 groups;

each R 2a is independently H, F, Cl, Br, I, —NO 2 , N 3 , CN, —OH, —NH 2 , C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxyl, C 3 -C 12 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl or 5-12 membered heteroaryl, wherein each of the C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxyl, C 3 -C 12 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, and 5-12 membered heteroaryl is optionally independently substituted by 1, 2, 3, 4 or 5 R 11 groups;

R 3 is H, C 3 -C 12 hydroxyalkyl, C 3 -C 12 alkyl, C 1 -C 12 haloalkyl, C 1 -C 12 aminoalkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 3 -C 12 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl, wherein each of the C 3 -C 12 hydroxyalkyl, C 3 -C 12 alkyl, C 1 -C 12 haloalkyl, C 1 -C 12 aminoalkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 3 -C 12 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heterocyclyl and 5-12 membered heteroaryl is optionally independently substituted by 1, 2, 3, 4 or 5 R 11 groups;

R 4 is C 1 -C 12 hydroxyalkyl, C 3 -C 12 alkyl, C 1 -C 12 haloalkyl, C 1 -C 12 aminoalkyl, C 2 -C 12 alkenyl, Cu alkynyl, C 3 -C 12 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl, wherein R 4 is optionally substituted by 1, 2, 3, 4 or 5 R 11 groups;

each of R 5 , R 6 , R 7 and R 8 is independently H, C 1 -C 12 hydroxyalkyl, C 3 -C 12 alkyl, C 1 -C 12 haloalkyl, C 1 -C 12 aminoalkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 3 -C 12 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl or 5-12 membered heteroaryl, wherein each of the C 1 -C 12 hydroxyalkyl, C 3 -C 12 alkyl, C 1 -C 12 haloalkyl, C 1 -C 12 aminoalkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 3 -C 12 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl is optionally independently substituted by 1, 2, 3, 4 or 5 R 11 groups;

each R 3a , R 4a , R 5a , R 6a , R 7a and R 8a is independently H, F, Cl, CN, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxyl, C 1 -C 12 alkylamino, —(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), —(C 0 -C 4 alkylene)-(3-12 membered heterocyclyl), C 6 -C 12 aryl or 5-12 membered heteroaryl, wherein each of the C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxyl, C 1 -C 12 alkylamino, —(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), —(C 0 -C 4 alkylene)-(3-12 membered heterocyclyl), C 6 -C 12 aryl and 5-12 membered heteroaryl is optionally independently substituted by 1, 2, 3, 4 or 5 R 11 groups;

each R 9a , R 9b , R 9c , R 10a , R 10b , R 10c and R 10e is independently H, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 12 alkynyl, C 1 -C 12 alkoxyl, C 3 -C 12 cycloalkyl, —(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), —(C 0 -C 4 alkylene)-(3-12 membered heterocyclyl), —(C 0 -C 4 alkylene)-(C 6 -C 10 aryl) or —(C 0 -C 4 alkylene)-(5-12 membered heteroaryl), or R 9a and R 9b , R 10a and R 10b taken together with the nitrogen atom to which they are attached form a 3-12 membered heterocyclyl group, wherein each of the C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxyl, C 3 -C 12 cycloalkyl, —(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), —(C 0 -C 4 alkylene)-(3-12 membered heterocyclyl), —(C 0 -C 4 alkylene)-(C 6 -C 10 aryl), —(C 0 -C 4 alkylene)-(5-12 membered heteroaryl) and 3-12 membered heterocyclyl group is optionally substituted by 1, 2, 3 or 4 substitutents independently selected from F, Cl, Br, CN, N 3 , —NO 2 , —OH, —NH 2 , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl and C 1 -C 6 alkylamino;

each R 10d and R 10f is independently C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxyl, C 3 -C 12 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, 5-12 membered heteroaryl, —(C 1 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), —(C 1 -C 4 alkylene)-(3-12 membered heterocyclyl), —(C 1 -C 4 alkylene)-(C 6 -C 12 aryl) or —(C 1 -C 4 alkylene)-(5-12 membered heteroaryl), wherein each of the above substituents is optionally substituted by 1, 2, 3 or 4 substitutents independently selected from F, Cl, Br, CN, N 3 , —OH, —NH 2 , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl and C 1 -C 6 alkylamino;

each R 11 is independently F, Cl, Br, I, CN, —NO 2 , N 3 , —OH, —NH 2 , C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 haloalkyl, C 3 -C 12 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heterocyclyl, 5-12 membered heteroaryl, C 1 -C 12 aminoalkyl, C 1 -C 12 alkylamino, C 1 -C 12 alkoxyl, C 1 -C 12 hydroxyalkyl, —NH(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), —NH(C 0 -C 4 alkylene)-(C 6 -C 12 aryl), —NH(C 0 -C 4 alkylene)-(3-12 membered heterocyclyl), —NH(C 0 -C 4 alkylene)-(5-12 membered heteroaryl), —N[(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl)] 2 , —N[(C 0 -C 4 alkylene)-(C 6 -C 12 aryl)] 2 , —N[(C 0 -C 4 alkylene)-(3-12 membered heterocyclyl)] 2 , —N[(C 0 -C 4 alkylene)-(5-12 membered heteroaryl)] 2 , —O—(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), —O—(C 0 -C 4 alkylene)-(C 6 -C 12 aryl), —O—(C 0 -C 4 alkylene)-(3-12 membered heterocyclyl) or —O—(C 0 -C 4 alkylene)-(5-12 membered heteroaryl); and

each m is independently 0, 1 or 2.

2. The compound of claim 1 , wherein Z is 8-11 membered spiro heterobicyclyl or 8-10 membered fused heterobicycloalkyl, wherein Z is substituted by 1, 2, 3 or 4 R 2 groups.

3. The compound of claim 1 , wherein Z is:

or a stereoisomer thereof, wherein each X, X′, X 2 , and X 3 is independently —CH 2 —, —NH— or —O—, with the proviso that X 2 and X 3 are not —O— simultaneously; and wherein Z is substituted by 1, 2 or 3 R 2 groups.

4. The compound of claim 1 , wherein Z is:

or a stereoisomer thereof, and wherein Z is substituted by 1, 2 or 3 R 2 groups.

5. The compound of claim 1 , wherein Z 1 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl or 4-7 membered heterocyclyl, wherein each of the C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and 4-7 membered heterocyclyl is optionally independently substituted by 1, 2 or 3 R 2a groups.

6. The compound of claim 1 , wherein R 1 is H, F, Cl, Br, I, N 3 , CN, —NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 4-7 membered heterocyclyl, —NR 9a R 9b , —OR 9c , —C(═O)OR 9c , —C(═O)NR 9a R 9b or —S(═O) 2 NR 9a R 9b , wherein each of the C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and 4-7 membered heterocyclyl is optionally independently substituted by 1, 2 or 3 R 11 groups.

7. The compound of claim 1 , wherein each R 2 is independently F, Cl, Br, I, —NO 2 , N 3 , CN, —OH, —NH 2 , —C(═O)CH 2 CN, —NHC(═O)CH 2 CN, —N(CH 3 )C(═O)CH 2 CN, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyl, 4-7 membered heterocyclyl, phenyl, 5-6 membered heteroaryl, —NR 10a R 10b , —O—(C 0 -C 3 alkylene)-R 10c , —O—(C 1 -C 3 alkylene)-OR 10c , —C(═O)R 10d , —OC(═O)R 10d , —N(R 10e )C(═O)R 10d , —C(═O)NR 10a R 10b , —N(R 10e )C(═O)NR 10a R 10b , —C(═O)N(R 10e )C(═O)R 10d , —S(═O) 2 R 10f , —N(R 10e )S(═O) 2 R 10f or —S(═O) 2 NR 10a R 10b , or two adjacent R 2 taken together with the atoms to which they are attached form a C 3 -C 6 cycloalkyl or 4-7 membered heterocycloalkyl group, wherein each of the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyl, 4-7 membered heterocyclyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl group is optionally independently substituted by 1, 2 or 3 R 11 groups;

each R 2a is independently H, F, Cl, Br, I, —NO 2 , N 3 , CN, —OH, —NH 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyl, 4-7 membered heterocyclyl, phenyl or 5-6 membered heteroaryl.

8. The compound of claim 1 , wherein R 3 is H, C 3 -C 6 hydroxyalkyl, C 3 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 aminoalkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, phenyl, 4-7 membered heterocyclyl or 5-6 membered heteroaryl, wherein each of the C 3 -C 6 hydroxyalkyl, C 3 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 aminoalkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, phenyl, 4-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally independently substituted by 1, 2 or 3 R 11 groups.

9. The compound of claim 1 , wherein R 3 is H, —CH 2 C(CH 3 ) 2 OH, —(CH 2 ) 2 CH 2 OH, —CH 2 CH(OH)CH 3 , piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiazolyl, pyrrolyl or oxazolyl, wherein each of the piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl, pyrrolyl or oxazolyl is optionally independently substituted by 1, 2 or 3 R 11 groups.

10. The compound of claim 1 , wherein R 4 is C 1 -C 6 hydroxyalkyl, C 3 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 aminoalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, phenyl, 4-7 membered heterocyclyl or 5-6 membered heteroaryl, wherein R 4 is optionally substituted by 1, 2, or 3 R 11 groups.

11. The compound of claim 1 , wherein each of R 5 , R 6 , R 7 and R 8 is independently H, C 1 -C 6 hydroxyalkyl, C 3 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 aminoalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 4-7 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, wherein each of the C 1 -C 6 hydroxyalkyl, C 3 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 aminoalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl is optionally independently substituted by 1, 2 or 3 R 11 groups.

12. The compound of claim 1 , wherein each R 3a , R 4a , R 5a , R 6a , R 7a and R 8a is independently H, F, Cl, CN, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 alkoxyl, C 1 -C 6 alkylamino, —(C 0 -C 3 alkylene)-(C 3 -C 6 cycloalkyl), —(C 0 -C 3 alkylene)-(4-7 membered heterocyclyl), phenyl or 5-6 membered heteroaryl, wherein each of the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 alkoxyl, C 1 -C 6 alkylamino, —(C 0 -C 3 alkylene)-(C 3 -C 6 cycloalkyl), —(C 0 -C 3 alkylene)-(4-7 membered heterocyclyl), phenyl and 5-6 membered heteroaryl is optionally independently substituted by 1, 2 or 3 R 11 groups.

13. The compound of claim 1 , wherein each R 9a , R 9b , R 9c , R 10a , R 10b , R 10c and R 10e is independently H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyl, —(C 0 -C 3 alkylene)-(C 3 -C 6 cycloalkyl), —(C 0 -C 3 alkylene)-(4-7 membered heterocyclyl), —(C 0 -C 3 alkylene)-phenyl, —(C 0 -C 3 alkylene)-(5-6 membered heteroaryl), or R 9a and R 9b , R 10a and R 10b taken together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclyl group, wherein each of the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyl, —(C 0 -C 3 alkylene)-(C 3 -C 6 cycloalkyl), —(C 0 -C 3 alkylene)-(4-7 membered heterocyclyl), —(C 0 -C 3 alkylene)-phenyl, —(C 0 -C 3 alkylene)-(5-6 membered heteroaryl), and 4-7 membered heterocyclyl group is optionally substituted by 1, 2 or 3 substitutents independently selected from F, Cl, Br, CN, N 3 , —NO 2 , —OH, —NH 2 , C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 hydroxyalkyl, C 1 -C 3 aminoalkyl and C 1 -C 3 alkylamino.

14. The compound of claim 1 , wherein each R 9a , R 9b , R 9c , R 10a , R 10b , R 10c and R 10e is independently H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, allyl, vinyl, propenyl, C 1 -C 4 alkoxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, -methylene-cyclopropyl, -ethylidene-cyclopropyl, -methylene-cyclobutyl, -ethylidene-cyclobutyl, -methylene-cyclopentyl, -ethylidene-cyclopentyl, -methylene-cyclohexyl, -ethylidene-cyclohexyl, alkylene)-(4-7 membered heterocyclyl), phenyl, pyridyl, pyridazinyl, pyrimidinyl, —(C 1 -C 3 alkylene)-phenyl or —(C 1 -C 3 alkylene)-(5-6 membered heteroaryl), wherein each of the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, allyl, vinyl, propenyl, C 1 -C 4 alkoxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, -methylene-cyclopropyl, -ethylidene-cyclopropyl, -methylene-cyclobutyl, -ethylidene-cyclobutyl, -methylene-cyclopentyl, -ethylidene-cyclopentyl, -methylene-cyclohexyl, -ethylidene-cyclohexyl, alkylene)-(4-7 membered heterocyclyl), phenyl, pyridyl, pyridazinyl, pyrimidinyl, —(C 1 -C 3 alkylene)-phenyl and —(C 1 -C 3 alkylene)-(5-6 membered heteroaryl) is optionally substituted by 1, 2 or 3 substitutents independently selected from F, Cl, Br, CN, N 3 , —NO 2 , —OH, —NH 2 , —CF 3 , —OCH 3 , —CH 2 OH, —CH 2 CH 2 OH, —NHCH 3 , —N(CH 3 ) 2 and —CH 2 NH 2 .

15. The compound of claim 1 , wherein each R 10d and R 10f is independently C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxyl, C 3 -C 6 cycloalkyl, 4-7 membered heterocyclyl, phenyl, 5-6 membered heteroaryl, —(C 1 -C 3 alkylene)-(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)-(4-7 membered heterocyclyl), —(C 1 -C 3 alkylene)-phenyl or —(C 1 -C 3 alkylene)-(5-6 membered heteroaryl), wherein each of the above substituents is optionally substituted by 1, 2 or 3 substitutents independently selected from F, Cl, Br, CN, N 3 , —OH, —NH 2 , C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 hydroxyalkyl, C 1 -C 3 aminoalkyl and C 1 -C 3 alkylamino.

16. The compound of claim 1 , wherein each R 10d and R 10f is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, allyl, vinyl, propenyl, phenyl, piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, C 1 -C 4 alkoxyl, methylene-cyclopropyl, -ethylidene-cyclopropyl, -methylene-cyclobutyl, -ethylidene-cyclobutyl, -methylene-cyclopentyl, -ethylidene-cyclopentyl, -methylene-cyclohexyl or -ethylidene-cyclohexyl, wherein each of the above substituents is optionally substituted by 1, 2 or 3 substitutents independently selected from F, Cl, Br, CN, N 3 , —OH, —NH 2 , —CF 3 , —OCH 3 , —CH 2 OH, —CH 2 CH 2 OH, —NHCH 3 , —N(CH 3 ) 2 and —CH 2 NH 2 .

17. The compound of claim 1 , wherein each R 11 is independently F, Cl, Br, I, CN, —NO 2 , N 3 , —OH, —NH 2 , methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, ethyoxyl, n-propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, methylamino, dimethylamino or aminomethyl.

18. The compound of claim 1 having one of the following structures:

or a stereoisomer, a tautomer, an N-oxide, a solvate, or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising the compound of claim 1 , and a pharmaceutically acceptable excipient, carrier, adjuvant, vehicle or a combination thereof.

20. The pharmaceutical composition of claim 19 further comprising a therapeutic agent selected from the group consisting of chemotherapeutic agents, anti-proliferative agents, phosphodiesterase 4 (PDE4) inhibitors, β 2 -adrenoreceptor agonists, corticosteroids, non-steroidal GR agonists, anticholinergic agents, antihistamines, anti-inflammatory agents, immunosuppressants, immunomodulators, agents for treating atherosclerosis, agents for treating pulmonary fibrosis and combinations thereof.

21. A method of treating or lessening the severity of a disease by inhibiting a protein kinase selected from JAK1, JAK2, Aurora A, Aurora B and FLT3, the method comprising administering to a patient the compound of claim 1 , wherein the disease is a cancer selected from head and neck cancer, prostate cancer, breast cancer, ovarian cancer, melanoma, lung cancer, brain tumor, pancreatic cancer and renal carcinoma, or

a disease selected from polycythemia vera, essential thrombocytosis, myelofibrosis, chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic obstruction pulmonary disease (COPD), asthma, systemic lupus erythematosis, cutaneous lupus erythematosis, lupus nephritis, dermatomyositis, Sjogren's syndrome, psoriasis, type I diabetes mellitus, allergic airway disease, sinusitis, eczema, hives, food allergies, allergies to insect venom, inflammatory bowel syndrome, Chron's disease, rheumatoid arthritis, juvenile arthritis and psoriatic arthritis, or

a graft-versus-host disease selected from organ transplant rejection, tissue transplant rejection and cell transplant rejection.

22. A method of treating or lessening the severity of a disease by inhibiting a protein kinase selected from JAK1, JAK2, Aurora A, Aurora B and FLT3, the method comprising administering to a patient the pharmaceutical composition of claim 19 , wherein the disease is a cancer selected from head and neck cancer, prostate cancer, breast cancer, ovarian cancer, melanoma, lung cancer, brain tumor, pancreatic cancer and renal carcinoma, or

a disease selected from polycythemia vera, essential thrombocytosis, myelofibrosis, chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic obstruction pulmonary disease (COPD), asthma, systemic lupus erythematosis, cutaneous lupus erythematosis, lupus nephritis, dermatomyositis, Sjogren's syndrome, psoriasis, type I diabetes mellitus, allergic airway disease, sinusitis, eczema, hives, food allergies, allergies to insect venom, inflammatory bowel syndrome, Chron's disease, rheumatoid arthritis, juvenile arthritis and psoriatic arthritis, or

a graft-versus-host disease selected from organ transplant rejection, tissue transplant rejection and cell transplant rejection.

23. A method of inhibiting the activity of a protein kinase by contacting the protein kinase with the compound of claim 1 , wherein the protein kinase is selected from JAK1, JAK2, Aurora A, Aurora B and FLT3.

24. A method of inhibiting the activity of a protein kinase by contacting the protein kinase with the pharmaceutical composition of claim 19 , wherein the protein kinase is selected from JAK1, JAK2, Aurora A, Aurora B and FLT3.